Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Is this a big deal?

<< Previous

Bullboard Posts

Next >>

Post by longterm56on Mar 21, 2021 1:09pm

220 Views

Post# 32847018

Is this a big deal?

I'm not sure I understand the impact of this article ... does this new data support the use of Egrifta for NASH or is this a completely different use of the drug? Since Egrifta is already approved, will this allow doctors to prescribe it for additional patients other than Lipo?

Thanks -

-LT

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?